Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A 24-year-old shared six-month progress on hair loss treatment using 1mg finasteride daily, 1ml 5% minoxidil once a day, and microneedling every two weeks. The hair appears stronger.

A 21-year-old is using 5mg Minoxidil, 1mg Dutasteride, Nizoral, and occasional microneedling for hair loss, seeing improvement on the left side of the scalp. They stopped microneedling due to scalp inflammation and are awaiting a dermatologist appointment.

A 31-year-old male switched from oral to topical dutasteride due to side effects and reduced oral minoxidil dosage after a 7000 graft hair transplant. He added dermastamping, topical retinol, and caffeine, seeking advice on the effectiveness of his new regimen.

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

A 30-year-old man shared his 9-year experience with hair loss treatments, including finasteride, minoxidil, and dutasteride, noting that while the medications were effective, they caused side effects like lower libido, gynecomastia, and mental health issues. He decided to stop all medications due to concerns about mood, fertility, and overall happiness.

A user shared their experience on day 9 after a hair transplant, mentioning the use of vitamin E oil and conditioner to remove scabs. They received positive feedback on their progress and were advised to be patient for noticeable results in a few months.

A 19-year-old is using topical minoxidil 7% and finasteride 0.1% foam, along with a laser cap, to combat hair loss. They report progress despite initial shedding and are considering switching to oral finasteride in the future for convenience.

A 25-year-old male experienced noticeable temple regrowth using 1mg finasteride, 2.5mg oral minoxidil, and 2mg GHK-Cu over three months. The user is pleased with the progress, especially on the left temple.

Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.

The user improved their hair with 0.5mg dutasteride, 2.5mg oral minoxidil, and a hair transplant of 2500 grafts in the frontal area over two years. They reported no significant side effects from the medication, except for reduced sexual function.

The user reported hair thickening after two months of using topical 7% minoxidil and 0.1% dutasteride, with no side effects. They previously experienced side effects with oral finasteride and switched to the topical treatment.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

The user has been using various hair loss treatments, including dutasteride, oral minoxidil, finasteride, RU58841, and dermarolling, but feels they may have lost hair and is considering a hair transplant. They are advised to stick to one treatment for 6-12 months to see results, as frequent changes may hinder progress.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

A 35-year-old male is experiencing diffuse thinning and is using finasteride, topical minoxidil, and dutasteride. He is considering a hair transplant but is advised to wait and continue with medications for now.

ET-02 (RS 5441) shows promising results for hair growth, performing better in humans than in mice. There is debate over the effectiveness compared to minoxidil, with some users wanting more detailed data.

JW0061 shows superior hair growth results compared to existing treatments, with significant increases in hair follicles. The Wnt/β-catenin pathway is crucial for hair growth, and JW0061 activates this pathway effectively.

A user shared their experience with a hair transplant, emphasizing the importance of avoiding caffeine 7 days before the procedure. Ignoring this advice led to reduced effectiveness of the numbing agent, causing significant discomfort during the transplant.

The user experienced hair improvement using a topical finasteride, minoxidil, and tretinoin combo, along with supplements like zinc, copper, magnesium, vitamin D3, K2, iodine, and boron. They believe these changes are due to addressing mineral deficiencies and possibly thyroid issues, despite skepticism from others.

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

RU58841 has significantly improved the user's hair loss experience, alongside oral finasteride, dutasteride, 5 mg minoxidil, topical finasteride, dermastamping, and low-level laser therapy. The user is considering increasing their RU58841 dose from 75 mg to 100-150 mg daily.

A user has been using finasteride since 2018, switched to dutasteride, and added minoxidil, microneedling, and a tretinoin/spiro compound. They are pleased with the results and hopeful for more improvement.

CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.

Topical finasteride (P-3074) can inhibit scalp DHT by up to 70%, with some users experiencing systemic absorption similar to oral use. Users discuss varying application frequencies and concentrations, with some noticing side effects when overused.

The user has been taking dutasteride for 7 months with unimpressive results and recently started using minoxidil once a day. They are inquiring about the effectiveness of using minoxidil twice a day and the addition of tretinoin to enhance results.

SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.

A 26-year-old male uses 0.5mg Dutasteride every other day and 5mg Minoxidil daily for hair loss, showing significant improvement in three months. He reports no side effects.

KX-826 combined with minoxidil significantly increases hair growth compared to minoxidil alone for treating male androgenetic alopecia, with no unexpected safety concerns. Users discuss various hair loss treatments, including KX-826, minoxidil, finasteride, and RU58841, sharing personal experiences and sourcing information.

Dr. Tsuji is giving online lectures about hair multiplication trials. Users express hope for a cure, but some are skeptical about its timeline.

A 55-year-old user shared progress pictures after 5 months of using dutasteride 6 times a week and minoxidil 2.5 mg daily, reporting hair regrowth and some side effects like mild erectile dysfunction and foot swelling. The user attributes recent hair loss to creatine and notes improvement after adjusting the treatment regimen.